Refine by
Respiratory Patient Articles & Analysis
69 news found
It is a point-of-care device for assessing airway inflammation in patients with respiratory problems. With over 45 million NIOX® tests undertaken to date, the system is used by healthcare professionals around the world to help improve asthma care. ...
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. ...
It can aid in the diagnosis of asthma and COPD and can also help identify patients who are at risk of progression to COPD. [1] The tremoflo® C-100 assesses respiratory function through simple tidal breathing and can be a valuable tool when compiling a detailed picture of respiratory function. It is particularly useful in enabling the very ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...
Marianna University School of Medicine, Department of Respiratory Medicine, Kawasaki, Japan. “Many patients with advanced disease continue to struggle to breathe, making even simple daily tasks difficult. ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
Proud to partner with Novus Medical to help respiratory clinicians improve the life of their patients through access to Simeox. The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, such as bronchiectasis, cystic fibrosis, ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
Such a move would enable more reproducible assessments, guide the design of treatment plans, and improve the practice of respiratory medicine for physicians and their patients. “Making image interpretation more reproducible, more quantitative, and more evidence-based is something that needs to happen,” states Krestin. ...
ByFluidda
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
“Our initial focus will be on the treatment of lower respiratory tract infections, for which there remains a significant unmet need. Our differentiated device technology platform has the potential to simplify the delivery of higher efficiency inhalation drug products, making effective therapies available for patients with compromised lung function.” ...
There are over 250 million people who suffer from lower respiratory tract infections (LTRI) every year and it is the 5th leading cause of death globally. The COVID-19 pandemic has highlighted the urgency for effective respiratory therapies. Inhaled anti-infectives dramatically improve the targeting of therapies to the site of respiratory ...
The initial targeted indications include: Post-operative Respiratory Depression. Respiratory depression is common in patients recovering from surgery and anesthesia. ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. ...
Broncholab™, developed and implemented by Fluidda, is a platform where CT-scan data of individual persons can be uploaded and analyzed with FRI-technology. The result of this analysis is then sent to the attending physician alone, observing all privacy requirements. Broncholab provides physicians with reproducible CT values for pulmonary tissue for providing quantitative support for ...
ByFluidda
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. ...
Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. It first inhales air, removes nitrogen, then generates a continuous oxygen source, and delivers concentrated oxygen to patients who need ...
Biocompatibility evaluation of breathing gas pathways in medical devices is a powerful tool for assessing contaminants from the air emitted from the device for Volatile Organic Compounds (VOCs) and particulate matter when the gas pathway is intended to contact a patient’s respiratory tract. STEMart now offers various services for Testing of Breathing Gas ...
BySTEMart